Bloodstream Infection Testing Market Size & Growth Forecast 2027–2036, By Segments (Sample Type, Technology, End-User, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Bloodstream Infection Testing Market size was over USD 815.9 million in 2026 and is likely to grow at a 4.28% CAGR between 2027 and 2036, attaining USD 1.24 billion by 2036. The industry revenue for 2027 is estimated at USD 845.27 million.
Get more details on this report
Request Free Sample ReportBloodstream Infection Testing Market Intelligence Snapshot
Regional Market Dynamics
- North America held 47.36% share in 2026, supported by established diagnostic networks, high hospital testing volumes, and integration of advanced platforms into clinical workflows.
- Asia Pacific is projected to grow at a 5.36% CAGR, driven by improving healthcare infrastructure and wider use of modern diagnostic methods.
Segment Momentum
- Blood Culture held a 71.81% share in 2026 because it remains the core sample type for confirming bloodstream infections and fits established hospital and laboratory diagnostic workflows.
- PCR led the market with a 62.69% share and the strongest growth momentum, driven by demand for rapid pathogen detection and faster turnaround times in urgent diagnostic settings.
Market Expansion Drivers
- Increasing incidence of infectious and healthcare-associated bloodstream infections driving advanced diagnostic testing demand.
- WHO-recommended blood screening protocols accelerating adoption of infection detection technologies in blood banks.
- Rising antimicrobial resistance concerns encouraging investments in rapid pathogen identification platforms.
Leading Market Participants
- Prominent companies in the bloodstream infection testing market include bioMérieux SA (France), Becton Dickinson and Company (United States), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (United States), Cepheid (United States), Seegene Inc. (South Korea), T2 Biosystems, Inc. (United States), Bruker Corporation (United States), Accelerate Diagnostics, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 815.9 million
- 2027 Estimated Market Size: USD 845.27 million.
- Projected Market Size: USD 1.24 billion by 2036
- Growth Forecast: 4.28% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Blood Culture (Sample Type) | PCR (Technology) | Hospitals & Diagnostic Centers (End-User) | Reagents & Consumables (Product)
- Emerging Opportunity Segment: Blood Culture (Sample Type) | PCR (Technology) | Hospitals & Diagnostic Centers (End-User) | Reagents & Consumables (Product)
Market Growth Drivers and Industry Trends
Increasing incidence of infectious and healthcare-associated bloodstream infections driving advanced diagnostic testing demand
The growing burden of infectious diseases and healthcare-associated bloodstream infections is strengthening the bloodstream infection testing market as healthcare providers require timely identification of pathogens to guide appropriate treatment. Bloodstream infections can progress rapidly and may involve diverse bacterial or fungal organisms, making accurate diagnostic testing essential for determining the causative pathogen and supporting clinical decision-making. Increasing attention to infection prevention, hospital-acquired infections, and improved patient management is encouraging healthcare facilities to adopt diagnostic approaches that can identify bloodstream pathogens with greater reliability and reduce delays associated with conventional testing workflows.
WHO-recommended blood screening protocols accelerating adoption of infection detection technologies in blood banks
The implementation of internationally recognized blood safety practices is supporting the bloodstream infection testing market by reinforcing the need for systematic screening of donated blood and blood products before transfusion. Blood banks require reliable detection technologies to identify infectious agents that could otherwise be transmitted to recipients, making screening an important component of transfusion safety and quality control. As healthcare systems strengthen blood collection and testing procedures in line with established recommendations, laboratories are increasingly incorporating sensitive diagnostic technologies capable of supporting consistent pathogen screening across blood donation workflows.
Rising antimicrobial resistance concerns encouraging investments in rapid pathogen identification platforms
Escalating concerns surrounding antimicrobial resistance are increasing demand for faster diagnostic information, thereby supporting the bloodstream infection testing market as clinicians seek to identify pathogens and inform treatment decisions more efficiently. Conventional diagnostic processes can require extended periods before the responsible organism is confirmed, potentially delaying the selection of appropriate antimicrobial therapy. Rapid molecular and other advanced identification platforms can shorten the diagnostic pathway by detecting pathogens directly or providing earlier organism-level information, helping healthcare providers distinguish infections requiring targeted antimicrobial management from cases where broader empirical treatment may be reconsidered.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing incidence of infectious and healthcare-associated bloodstream infections driving advanced diagnostic testing demand | 1.90% | High | North America, Europe | High | Near Term |
| WHO-recommended blood screening protocols accelerating adoption of infection detection technologies in blood banks | 1.60% | High | Asia Pacific, Africa | High | Mid Term |
| Rising antimicrobial resistance concerns encouraging investments in rapid pathogen identification platforms | 1.30% | Moderate | Europe, North America | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held a 47.36% share of the bloodstream infection testing market in 2026, supported by advanced diagnostic infrastructure, strong hospital laboratory capabilities, and high clinical emphasis on rapid identification of bloodstream infections. The need to reduce diagnostic delays and guide appropriate antimicrobial treatment is encouraging healthcare providers to adopt increasingly sophisticated molecular and automated testing approaches. Established infection-control practices and continued investment in hospital diagnostics further strengthen regional demand.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region as healthcare systems expand laboratory capacity and place greater emphasis on early detection of severe infections. Rising hospital utilization, improvements in diagnostic infrastructure, and increasing awareness of antimicrobial resistance are supporting wider adoption of rapid bloodstream infection testing. Greater investment in modern laboratory technologies is also helping healthcare facilities strengthen diagnostic capabilities and improve the management of serious infectious diseases.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Laboratory IntegrationGermany prioritizes bloodstream infection testing solutions that combine diagnostic accuracy with standardized laboratory operations. German healthcare institutions continue adopting advanced microbiology platforms that enhance pathogen identification while supporting efficient hospital infection management practices.
France 🇫🇷
Hospital Diagnostic OptimizationFrance advances bloodstream infection testing through expanded use of rapid diagnostic technologies within hospital microbiology laboratories. French healthcare providers prioritize solutions that improve diagnostic consistency and support evidence-based antimicrobial prescribing across acute care environments.
Italy 🇮🇹
Infection Control SupportItaly continues enhancing bloodstream infection testing capabilities to strengthen hospital infection control and patient management. Italian laboratories increasingly adopt automated identification and susceptibility testing systems that improve diagnostic confidence while streamlining laboratory operations.
Japan 🇯🇵
Clinical Workflow EfficiencyJapan focuses on bloodstream infection testing technologies that reduce diagnostic turnaround times while fitting established hospital laboratory processes. Japanese healthcare providers emphasize dependable testing systems that support early intervention for patients with suspected sepsis and bloodstream infections.
South Korea 🇰🇷
Automated Diagnostic ExpansionSouth Korea strengthens its bloodstream infection testing market through investments in laboratory automation and molecular diagnostic capabilities. South Korean hospitals increasingly implement integrated testing solutions that improve operational efficiency and accelerate pathogen detection for critical care settings.
United States 🇺🇸
Rapid Diagnostic AdoptionThe U.S. bloodstream infection testing market emphasizes rapid molecular diagnostics and automated laboratory workflows to improve clinical decision-making. Healthcare providers in the U.S. increasingly integrate high-throughput testing platforms with antimicrobial stewardship programs to support timely and targeted treatment.
Segment Leadership and Growth Trends
Bloodstream Infection Testing Market Share (%), by Sample Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportSample Type Segment Analysis: Blood Culture (Largest & Fastest-Growing Segment)
The blood culture segment dominated the bloodstream infection testing market with a 71.81% share in 2026 and is also expected to be the fastest-growing segment, reflecting its fundamental role in detecting and identifying pathogens associated with bloodstream infections. Blood culture testing remains widely used because it supports the isolation of causative microorganisms and can guide subsequent diagnostic and treatment decisions. The rising need for timely identification of severe infections, particularly in hospital and critical care settings, continues to support its adoption. Advances in culture systems, laboratory automation, and complementary identification methods are improving workflow efficiency and diagnostic performance, further strengthening the segment's growth prospects.
Technology Segment Analysis: PCR (Largest & Fastest-Growing Segment)
PCR dominated the bloodstream infection testing market with a 62.69% share in 2026 and is also positioned as the fastest-growing technology segment, driven by the increasing need for rapid and sensitive detection of infectious pathogens. PCR-based testing can support faster identification by detecting pathogen-specific genetic material, helping clinicians make more informed treatment decisions when timely intervention is critical. The technology's ability to detect multiple targets and integrate into modern diagnostic workflows is supporting its expanding use across clinical laboratories. Continued demand for quicker diagnostic turnaround, improvements in molecular testing platforms, and the growing focus on reducing delays in infection management are expected to reinforce the segment's leading position.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Sample Type | Whole Blood, Blood Culture | Blood Culture | Blood Culture |
| Technology | PCR, Mass Spectroscopy, In Situ Hybridization, Others | PCR | PCR |
| End-User | Hospitals & Diagnostic Centers, Custom Laboratory Service Providers, Academic & Research Institutes, Others | Hospitals & Diagnostic Centers | Hospitals & Diagnostic Centers |
| Product | Reagents & Consumables, Instruments | Reagents & Consumables | Reagents & Consumables |
Competitive Landscape and Market Positioning
Prominent players in the bloodstream infection testing market:
1. bioMérieux SA (France)
2. Becton Dickinson and Company (United States)
3. F. Hoffmann-La Roche Ltd (Switzerland)
4. Siemens Healthineers AG (Germany)
5. Thermo Fisher Scientific Inc. (United States)
6. Cepheid (United States)
7. Seegene Inc. (South Korea)
8. T2 Biosystems Inc. (United States)
9. Bruker Corporation (United States)
10. Accelerate Diagnostics Inc. (United States)
The bloodstream infection testing market is experiencing strong innovation activity focused on rapid pathogen detection and improved diagnostic accuracy. Manufacturers are investing in molecular testing technologies and automated laboratory solutions that reduce turnaround times and support timely treatment decisions. Rising emphasis on infection control and early diagnosis is strengthening competitive development within the bloodstream infection testing market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| bioMérieux SA (France) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| F. Hoffmann-La Roche Ltd (Switzerland) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Cepheid (United States) | |||||||
| Seegene Inc. (South Korea) | |||||||
| T2 Biosystems Inc. (United States) | |||||||
| Bruker Corporation (United States) | |||||||
| Accelerate Diagnostics Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Accelerate Diagnostics, Inc. | Oct-25 | Accelerate Diagnostics, Inc. rolled out upgraded phenotypic antimicrobial susceptibility testing platforms featuring integrated rapid pathogen identification systems. This commercial launch scales hospital testing workflows by accelerating actionable resistance profile reporting to support targeted critical care interventions. |
| BD | Aug-25 | BD commercialized advanced artificial intelligence-assisted microbiology workflow solutions designed specifically for bloodstream infection diagnostics. The technology integration scales laboratory automation and streamlines critical processing paths to enhance the detection and analysis of high-risk blood pathogens. |
| bioMérieux SA | Nov-24 | bioMérieux SA expanded its clinical diagnostics footprint by integrating enhanced molecular identification capabilities directly into its automated blood culture testing portfolio. The platform upgrade optimizes automated pathogen detection for laboratories managing intensive care or high-volume diagnostic workloads. |
| T2 Biosystems, Inc. | May-24 | T2 Biosystems, Inc. updated its direct-from-blood molecular diagnostic testing infrastructure to improve clinical precision in emergency sepsis management. The product optimization enables the identification of systemic bloodstream pathogens without requiring a traditional, time-intensive pre-culture incubation stage. |
| Cepheid | Apr-23 | Cepheid launched rapid multiplex polymerase chain reaction panels optimized for rapid bloodstream pathogen identification and genotypic resistance profiling. The product deployment scales high-throughput molecular diagnostics to support hospital-based antimicrobial stewardship and clinical decision-making. |
| T2 Biosystems, Inc. | Jul-22 | T2 Biosystems, Inc. received United States Food and Drug Administration clearance for its T2Lyme Panel, designed to optimize clinical workflows for detecting sepsis-causing pathogens. The diagnostic solution enables physicians to identify target resistance genes directly from patient samples, minimizing antibiotic misuse and accelerating time-to-treatment. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Bloodstream Infection Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Pathogen Type | Bacterial, Fungal, Viral, Polymicrobial |
| Clinical Indication | Sepsis, Septic Shock, Bacteremia, Fungemia |
| Test Purpose | Initial Diagnosis, Pathogen Identification, Antimicrobial Susceptibility Testing, Treatment Monitoring |
Bloodstream Infection Testing Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Hospital Antimicrobial Stewardship Program Opportunity Assessment |
|
| Sepsis Care Pathway Adoption Analysis |
|
| Laboratory Automation Readiness Assessment |
|
Need a different cut of the data?
Request Custom ResearchHow much revenue does the bloodstream infection testing market generate?
How much is the bloodstream infection testing industry expected to grow by 2036?
How are healthcare-associated bloodstream infections influencing diagnostic technology adoption?
Why are rapid pathogen identification platforms becoming a procurement priority in the bloodstream infection testing market?
Why does blood culture dominate the bloodstream infection testing market?
What makes PCR the fastest-growing technology in the bloodstream infection testing market?
What drives North America’s leadership in the bloodstream infection testing market?
How is Asia Pacific accelerating growth in bloodstream infection testing adoption?
What are the prominent companies operating in the bloodstream infection testing landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization